TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin Versus Placebo as an Add on for Complex Regional Pain Syndrome (CPRS) of the Upper Limb Managed by Stellate Ganglion Block (The PREGA Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with CRPS Type I as per the IASP (International Association for the Study of Pain) criteria which states presence of an initiating noxious event, or cause for immobilization~* Evidence at some point of swelling, color change, hot/cold/sweaty sensation and no other condition which can account for the pain and dysfunction of the upper limb~* Men or women between ages 18-65 year old~* Women should not be pregnant or breast feeding~* No change in treatment for 4 weeks prior to recruitment~* Pain scores of 4/10 on a verbal analogue scale~Exclusion Criteria:~* Patients with a neurologic disorder unrelated to CRPS~* Patients who are already on pregabalin~* Patients with renal impairment whose creatinine clearance is less than 60 ml/min~* Patients with congestive heart failure who are also diabetic and taking thiazolidinedione medication like rivoglitazone~* Unstable psychiatric history~* Patients with another problem with equal or worse pain~* Unstable medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
- 2 (Type: PLACEBO_COMPARATOR): Ten patients will be be in the placebo group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Steroid Delivery to the Frontal Sinus Opening With a Bioabsorbable Implant vs. a Bioabsorbable Nasal Dressing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 and older~* Diagnosis of chronic rhinosinusitis with nasal polyps based on the American Academy of Otolaryngology-Head and Neck Surgery guidelines~* Patient scheduled for bilateral endoscopic sinus surgery with evidence of bilateral frontal sinus disease based on Computed Tomography (Lund-Mackay score greater than or equal to 1)~* At the time of surgery bilateral frontal sinusotomy of type Draf 2a or 2b was performed using the same technique on both sides~* Bilateral endoscopic sinus surgery performed successfully without complication~* Frontal sinus opening diameter greater than 4.0 mm achieved (4 mm olive tipped suction easily passed into frontal sinus)~Exclusion Criteria:~* Any patient who had frontal sinus surgery for tumor~* Allergy to mometesone and/or triamcinolone~* Frontal sinusotomy type Draf 1 or Draf 3 performed~* One or both frontal sinus openings not amenable to implant placement~* Patients with chronic oral steroid dependent conditions~* Invasive fungal sinusitis~* Immune deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bioabsorbable steroid releasing sinus implant & nasal dressing impregnated with steroid (Type: EXPERIMENTAL): Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed incurable oligodendroglioma that progressed during or is recurrent or residual after initial therapy, including radiotherapy and/or chemotherapy~* Measurable tumor by MRI scan performed within two weeks prior to study entry~* Tumor must be at least 5 mm~* No brain stem tumors~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease (e.g., chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections~* No other serious concurrent disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* At least 4 weeks since prior immunotherapy~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* See Disease Characteristics~* At least 8 weeks since prior radiotherapy~Surgery:~* Recovered from any prior surgery~Other:~* No prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women \> 18 years,~* Operated for a breast cancer by mastectomy with or without lymph node dissection, without immediate reconstruction,~* Capable of understanding the antalgic protocol,~* No contraindication to the local anesthesics,~* Social security affiliation,~* Signed informed consent.~Exclusion Criteria:~* Preoperative radiotherapy,~* Local infection,~* Contra-indication to the local anesthetic or to CCP,~* Contra-indication for the use of morphine,~* Contra-indication for the use of remifentanil,~* Addiction to opioid analgesics know or not,~* Allergy to local anesthetics,~* Hepatic or renal impairment grim known,~* Previous surgery on the operated breast,~* Pregnant women, or child-bearing potential, or lactating women,~* Patient deprived of liberty or under supervision of a guardian.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine (Type: EXPERIMENTAL): Ropivacaine
- placebo (Type: PLACEBO_COMPARATOR): physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Airway Dimension Study in Children Undergoing MRI Sedated With Propofol and Dexmedetomidine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children undergoing MRI brain~* Age 2 - 5 yrs~* ASA I - II~Exclusion Criteria:~* OSA~* Pathology of upper airway~* Craniofacial anomalies~* Gastroesophageal reflux~* Increased intracranial pressure~* Body weight of 20% more than ideal~* Contraindication to the use of either drug~* Failure to maintain a patent airway during the study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: ACTIVE_COMPARATOR): None
- propofol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Documented Metabolic Syndrome by at least 3 of the following parameters:~* Abdominal obesity, assessed by waist circumference (for men \>103 cm, for women \>88 cm).~* Triglycerides \> 150 mg/dl.~* HDL cholestrol (for men \<40 mg/dl, for women \<50 mg/dl).~* Blood pressure \> or equal to 130/85 mm Hg.~* Fasting serum glucose \> or equal to 110 mg/dl.~* HIV RNA \< 50 copies/mL.~* IP within 3 months prior to selection.~Exclusion Criteria:~-Treated Metabolic Syndrom

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of T2000 in Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed essential tremor by NIH criteria~* Significant functional activity limitation due to ET~* Patients who have failed, are inadequately treated or cannot tolerate alternative treatments for ET as well as treatment naïve patients who have considered but declined alternative treatment~Exclusion Criteria:~* Patients adequately controlled without side effects on a current ET treatment~* Pregnant patients or patients who may become pregnant during the study~* Patients with other medical conditions that may cause tremor, such as Parkinson's disease or active hyperthyroidism~* Patients taking medications that might produce tremor or interfere with the evaluation of tremor such as CNS-stimulants or beta-blockers~* Patients who must take medications that alter liver metabolism as well as patients with liver disease or coagulation disorders~* Patients with seizure disorders~* Patients with a history of allergy or hypersensitivity reaction to barbiturates or other related medications, such as phenobarbital or phenytoin~* Patient with significant general medical or clinical laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): T2000 dose escalation
- 2 (Type: EXPERIMENTAL): Placebo followed by T2000 dose escalation
- 3 (Type: EXPERIMENTAL): Placebo followed by T2000 dose escalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aspen™ Ultrasound System and Aspen Rehabilitation Technique in the Treatment of Capsular Contracture

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Stage I:~* Age 22 years or greater,~* Cosmetic breast augmentation,~* Baker Grade III capsular contracture, subglandular implant position, saline implants.~Stage II:~* Age 22 years or greater,~* Cosmetic breast augmentation,~* Baker Grade III capsular contracture, subglandular or submuscular implant position, saline or silicone gel implants.~Exclusion Criteria:~* History of breast cancer,~* prior radiation therapy to chest wall,~* ruptured breast implant,~* calcification of capsules seen on any imaging study,~* implants \> 15 years old,~* prior treatment for capsular contracture in past 12 months (open capsulectomy, open capsulotomy, implant exchange, implant plane change, placement of acellular dermal matrix, explantation, closed capsulotomy, or oral medication),~* metal implants,~* pacemakers,~* defibrillators,~* history of epilepsy,~* history of bleeding, and undiagnosed pain syndromes,~* pregnancy,~* currently lactating,~* acute and sub-acute thrombosis and thrombophlebitis,~* potentially malignant tumors,~* benign tumors,~* malignancy,~* third-degree musculotendinous lesions,~* multiple sclerosis,~* osteomyelitis,~* cardiac arrhythmias,~* acute sepsis of tissue or bone,~* arteriosclerosis,~* hemophilia, and~* sensory nerve damage.

- Gender: FEMALE
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Patients (Type: EXPERIMENTAL): In stage I, 10 women aged 22 years or older who have received silicone or saline breast implants for subglandular or submuscular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Removal of Palpable Subdermal Contraceptive Rod Implants.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female age 18 or older~* Willing to remove a palpable subdermal Implanon/ Neplanon CI~* Willing and able to give written informed consent for participation in the investigation~* Willing to provide follow-up information according to the Clinical Investigators Brouchure~Exclusion Criteria:~* Known allergy to local anaesthetic (lidocaine/lignocaine) or disinfectant (chlorhexidine).~* Active skin lesion over the CI.~* The Investigator considers the subject unlikely to comply with investigational procedures, restrictions and requirements.~* Any contraindication for removal of the PI, as judged by the Investigator.~* Any disorders or medications that might affect coagulation, as judged by the Investigator.~* Any conditions suspected to affect healing or increase risk of infection (e.g. keloid tendency, diabetes or any upper arm dermatological condition that may affect upper arm healing).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New IMD (Type: EXPERIMENTAL): Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CDH between 20 and 36 weeks estimated gestational age (EGA)~* Only one of the following fetal criteria and one of the following postnatal criteria must be met for enrollment. Fetal criteria: an ultrasound (US)-obtained observed to expected lung to head ratio (o/e LHR) less than or equal to 35% or 2) a fetal magnetic resonance imaging (fMRI)- obtained observed to expected total fetal lung volume (o/e TFLV) less than or equal to 35%. Postnatal criteria: 1) Cord blood gas (CBG) with potenital hydrogen (pH) \<7.0, 2) Arterial blood gas (ABG) with pH \<7.2 on 2 gasses within the first 24 hours, 3) Preductal oxygen saturation (O2 sat) \<90% x 2 total hours (not necessarily consecutive) within the first 24 hours, or 4) Oxygenation Index (OI) \>20 x 2 total hours (not necessarily consecutive) within the first 24 hours.~Exclusion Criteria:~* Genetic/chromosomal abnormality: Trisomy 21, Trisomy 18, Trisomy 13 or other, significant genetic abnormality. Microdeletions or other mild genetic abnormalities are not considered exclusionary.~* Severe/major cardiac anomaly: coarctation of the aorta, combined atrial and ventricular septal defects, hypoplastic left heart syndrome, tetralogy of fallot, double outlet right ventricle, atrioventricular canal defects, or other hemodynamically significant defects.~* Moderate/severe neurologic / intracranial abnormality: Grade III or IV intraparenchymal hemorrhage, space occupying mass or lesion, or clinically significant traumatic lesion such as a subdural or epidural hemorrhage.~* Prematurity \<30 weeks estimated gestational age (EGA): Birth at 29 6/7 weeks or before~* Participation in an alternative prenatal intervention study: Fetoscopic Endotracheal Occlusion (FETO)~* Unwillingness / inability to return for follow-up evaluation and assessment

- Gender: ALL
- Minimum Age: 10 Minutes
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- Autologous umbilical cord blood (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Control of Chronic Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Gestational age ≥ 24 weeks~* Singleton gestation~* Chronic hypertension as defined as two elevated blood pressures (SBP ≥ 140mmHg and/or DBP ≥ 90mmHg) at least 4 hours apart before 20 weeks gestation~Exclusion Criteria:~* Known allergic reaction to labetalol~* Persistent mild-moderate asthma (≥ 2 rescue inhaler uses per week in the previous month)~* Obstructive airway disease~* Bradycardia \< 70 beats/min~* Heart block \> 1st degree or history of heart failure

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental labetalol dose (Type: EXPERIMENTAL): Subjects receive 40mg, 60mg, 80mg after each severe BP
- Current standard of care (Type: ACTIVE_COMPARATOR): Subjects receive 20mg, 40mg, 60mg after each severe BP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues